Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.
African American women are underdiagnosed with HER2-positive endometrial cancer, revealing a disparity that targeted genetic testing could help address.
ERBB2 amplification is significantly more prevalent in endometrial cancer patients of African ancestry (12%) compared to European ancestry (7%) in a large clinicogenomic database (n=16,073), co-occurring with serous histology and TP53 mutations. Additionally, 22% of non-amplified tumors show HER2 IHC 2+/3+ staining, highlighting underserved access to HER2-targeted precision therapy and the need for equitable testing strategies.
What the study was
- Study design
- retrospective large clinicogenomic database analysis
- Population
- Endometrial cancer patients, Foundation Medicine CGDB (n=16,073)
- Sample size
- 16073
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- JCO precision oncology
Why it surfaced
Largest genomic CGDB analysis (n=16,073) of ERBB2amp in EC; racial disparity finding actionable for equity in precision therapy access; Foundation Medicine/Flatiron CGDB real-world validity; directly addresses T5 precision oncology watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.